

**Novacyt S.A.**

**("Novacyt" or the "Company")**

**Director/PDMR Shareholding**

Paris, France and Camberley, UK – 15 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 14 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Average price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital
James McCarthy	Chief Financial Officer	39,670	£2.02	49,670	0.07%

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	James McCarthy, Chief Financial Officer
2.	Reason for the Notification	
a)	Position/status	See 1(a) - classified as a PDMR of the Company
b)	Initial notification/ Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Novacyt S.A.
b)	LEI	213800BWAC2BF295EG28
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each							
	Identification code	FR0010397232							
b)	Nature of the transaction	Acquisition of Ordinary Shares							
c)	Price(s) and volume(s)	<table><tr><td>Price</td><td>Volume</td></tr><tr><td>£2.01</td><td>37,310</td></tr><tr><td>£2.12</td><td>2,360</td></tr></table>		Price	Volume	£2.01	37,310	£2.12	2,360
Price	Volume								
£2.01	37,310								
£2.12	2,360								
d)	Aggregated information:  · Aggregated volume  · Price	<table><tr><td>Price</td><td>Volume</td></tr><tr><td>£2.02</td><td>39,670</td></tr></table>		Price	Volume	£2.02	39,670		
Price	Volume								
£2.02	39,670								
e)	Date of the transaction	14 March 2022							
f)	Place of the transaction	AIM							

– End –

### **Contacts**

#### **Novacyt SA**

David Allmond, Chief Executive Officer  
 James McCarthy, Chief Financial Officer  
 +44 (0)1276 600081

#### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
 Vadim Alexandre / Rob Rees (Corporate Broking)  
 +44 (0)20 3470 0470

#### **Numis Securities Limited (Joint Broker)**

Freddie Barnfield / James Black  
+44 (0)20 7260 1000

**Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

**FTI Consulting (International)**

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [Alex.Shaw@fticonsulting.com](mailto:Alex.Shaw@fticonsulting.com) /

[Novacyt.group@fticonsulting.com](mailto:Novacyt.group@fticonsulting.com)

**FTI Consulting (France)**

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

**About Novacyt Group**

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)